Trial reportPloS one2026
Measurement properties of the 30-second sit-to-stand test in post COVID-19 condition: Results from the PYCNOVID randomised controlled trial.
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05890534 (Pycnogenol® in People With Post-COVID-19 Condition), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pycnogenol® in People With Post-COVID-19 Condition: a Quadruple-blind, Randomized, Placebo-controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 30-second sit-to-stand test (30s-STS) is a frequently used measure of functional capacity in post-COVID-19 condition (PCC), but its measurement properties have not been comprehensively investigated.
methodsWe used data from the PYCNOVID randomised controlled trial to examine feasibility, safety, test-retest reliability, construct validity (correlations with key symptoms and physical activity), and responsiveness to change of the 30s-STS. Data were collected at screening, at baseline (approximately 2 weeks after screening), and at follow-up (12 weeks after baseline). Using screening and baseline data, agreement was evaluated using Bland-Altman analysis (mean bias and limits of agreement), alongside the intraclass correlation coefficient (ICC) and the minimal detectable change (MDC95). Correlation coefficients were used to assess relationships between the 30s-STS test, physical activity, and key PCC-related symptoms. The minimal important difference (MID) was estimated with data from baseline and at 12-weeks using anchor- and distribution-based methods.
resultsData from 150 adults with PCC (74.7% female) were analysed. The 30s-STS was safe (no adverse event) and feasible. Overall, test performance was reduced, 46% of participants had z-score values below the 5th percentile. The test showed good test-retest reliability (ICC 0.82 [95% CI, 0.76 to 0.86]) with no indication for a systematic learning effect; however, the limits of agreement were wide. Mean bias between was 0.84 repetitions (95% CI, 0.26 to 1.42). The MDC95 was 4.25 repetitions. Correlations with physical activity and key PCC-related symptoms were weak. Distribution-based methods yielded MID values between 1.38 and 3.23 repetitions. Change correlations between 30s-STS repetitions and the anchors were insufficient for anchor-based MID calculation.
conclusionsThe 30s-STS test is feasible, safe, and demonstrates good test-retest reliability. Changes exceeding four repetitions surpass measurement error (MDC95), while distribution-based estimates suggest a provisional MID of two repetitions. Further studies are needed to establish a triangulated MID to better capture patient-relevant change.
trial registrationClinicalTrials.gov, NCT05890534.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.